RECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both marketsRECELL GO is AVITA Medical’s ...

VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today ...

Cohealyx® multi-center study interim analysis and new case data to be presentedRECELL® and PermeaDerm® data reinforce a comprehensive approach to ...

VALENCIA, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AVITA Medical (RCEL) ®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company, today ...

VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced ...

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform ...

Avita Medical entered an agreement worth up to $25.5 million with a research unit of the Department of Health and Human Services to supply the government with treatments for burn mass casualty ...

AVITA Medical ®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award ...

Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populations VALENCIA, Calif., Nov. 03, ...